Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–63 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo for dupilumab Clear all

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 75
States / cities: Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more

Conditions: Eosinophilic Oesophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib 200 mg, Dupilumab 300 mg; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more

Conditions: Pruritis
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Dermatitis, Atopic
Interventions: Placebo, Bermekimab, Dupilumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Santa Ana, California • Orange Park, Florida + 15 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Placebo (for Dupilumab); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 50 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Sinusitis
Interventions: dupilumab, placebo; Biological · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aspirin-exacerbated Respiratory Disease
Interventions: Dupilumab; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more

Conditions: Asthma
Interventions: Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 50
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 42 more

Conditions: Asthma, Allergic
Interventions: Dupilumab, House Dust Mites (HDM), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions: Dupilumab, Omalizumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more

Search by objective public record fields.

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Dupilumab for Aspirin-exacerbated Respiratory Disease

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Dupilumab Effects Against Aeroallergen Challenge

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients